The Video Conference Celebrating the Signing of the Memorandum of Understanding on Cooperation between Tianjin Medical University Cancer Institute & Hospital and the Japan National Cancer Center Hospital
On September 1st, Tianjin Medical University Cancer Institute & Hospital (TMUCIH) and Japan’s National Cancer Center Hospital (NCCH) Celebrated the Signing of the Memorandum of Understanding on Cooperation with a video conference. This was attended by Prof. Kazuaki Shimada, Director of NCCH, Prof. Hiroyuki Fujimoto, Deputy Director, Clinical Management of NCCH, Prof. Noboru Yamamoto, Deputy Director, Research of NCCH along with other doctors and researchers from NCCH; Prof. Wei Lu, Party Secretary of TMUCIH, Prof. Kexin Chen and Prof. Yi Ba, Vice Presidents of TMUICH, Prof. Hui Li, Director, Dept. of Science and Education, TMUCIH along with surgeons and researchers from TMUCIH, who had trained at and visited NCCH.
This July, Prof. Jihui Hao, President of TMUCIH and Prof. Kazuaki Shimada, Director of Japan’s NCCH signed the Memorandum of Understanding on Cooperation between the two institutions.
During the video conference, Prof. Kazuaki Shimada, Director of NCCH and Prof. Wei Lu, Party Secretary of TMUCIH, both delivered the speeches. Prof. Hiroyuki Fujimoto, Deputy Director, Clinical Management of NCCH and Prof. Susumu Hijioka, Assistant Chief, Hepatobiliary and Pancreatic Oncology of NCCH presented their clinical work and exchanged their ideas with our experts. Prof. Chuntao Gao, Director of Dept. of Pancreatic Cancer, TMUCIH, gave a speech on behalf of all the doctors, who had trained at NCCH. These productive exchanges will open a new chapter for future collaboration between the two institutions.
Prof. Wei Lu, Party Secretary of TMUCIH,delivered the speech
Prof. Chuntao Gao, Director of Dept. of Pancreatic Cancer, TMUCIH,
gave a speech on behalf of all the doctors, who had trained at NCCH
The National Cancer Center (NCC) was founded as a hub for cancer treatment and research by the Japanese central government in 1962. Since then it has led Japan’s cancer treatment, prevention and control programs, research and education. In 1992, NCC established the East Hospital (Kashiwa campus) site, while one of the original units of NCC was transformed into the NCC-Hospital (Tsukiji campus) and NCC’s research institute was set up there in 1994. NCCH leads Japan’s cancer care and research, and is famous for its wide range of disciplines, logical scientific branches and interdepartmental collaboration.
TMUCIH and NCCH have already realized some achievements in faculty exchange, academic research, educational and training programs. Since 2009, TMUCIH has dispatched 4 doctors: Dr. Xiaojing Guo of Dept. of Breast Pathology, Drs. Yong Tang and Chuntao Guo of Dept. of Pancreatic Cancer, and Dr. Bin Ke of Dept. of Gastroenterological Cancer to visit NCC, facilitating interactions and collaboration.
In November, 2018, Prof. Kazuaki Shimada was invited to attend the Third International Conference on Cancer Translational Research and gave a keynote lecture in Tianjin. And he was appointed as an Honorary Professor of TMUCIH during that Conference.
In June, 2019, Prof. Jihui Hao led a delegation from TMUCIH to visit NCCH and conduct academic exchanges, which enhanced mutual understanding and laid a sound foundation for future collaboration focusing on faculty exchanges, education and training programs, and joint symposia.
At such a critical moment in the global fight against COVID-19, TMUCIH is actively expanding into new international cooperative relations and seeking new developments, and has formally established a cooperative relationship with NCCH to promote substantial collaboration in cancer diagnosis and treatment and scientific research and education through "on-line dialogue" between the two sides.
The signing of the MOU marks an important milestone for the strategic partnership. The two institutions will establish a mechanism for promoting collaboration through faculty visits, academic exchange, clinical trials, joint education and training, and bilateral symposia. We will combine forces and work together to build a high-level academic multidisciplinary exchange platform for our experts and scholars. We believe, our close and extensive interactions will help us raise all aspects of our collaborative work to a higher level.
